Expression and pharmacological evaluation of fusion protein FGF21-L-Fc / 药学学报
Acta Pharmaceutica Sinica
; (12): 787-792, 2011.
Article
in Chinese
| WPRIM (Western Pacific)
| ID: wpr-233055
Responsible library:
WPRO
ABSTRACT
FGF21 (fibroblast growth factor 21) is a recently described member of the FGF family. It has been previously demonstrated that FGF21 is a potent regulator of glucose homeostasis. To improve stability of FGF21 for better efficacy, a new form of recombinant FGF21 was generated by fusion of a full length FGF21 gene and the Fc fragment of human IgG4 with flexible linker sequence. To examine the glucose regulation activity of FGF21-L-Fc, 3T3-L1 pre-adipocytes were differentiated into adipocytes, and glucose uptake activity of FGF21-L-Fc was examined by glucose oxidase and peroxidase (GOD-POD) assay. The results showed that in comparison with wild type FGF21, FGF21-L-Fc was more potent in stimulation of glucose uptake by 3T3-L1. In vivo studies on the modified protein demonstrated that FGF-L-Fc had a better efficacy in lowering blood glucose of the STZ-induced diabetic animals and controlled glucose level for a longer time. The results provided a sound basis for further studies.
Full text:
Available
Health context:
Neglected Diseases
Health problem:
Neglected Diseases
/
Zoonoses
Database:
WPRIM (Western Pacific)
Main subject:
Pharmacology
/
Blood Glucose
/
Recombinant Proteins
/
Immunoglobulin G
/
Adipocytes
/
3T3-L1 Cells
/
Diabetes Mellitus, Experimental
/
Drug Therapy
/
Escherichia coli
/
Fibroblast Growth Factors
Limits:
Animals
Language:
Chinese
Journal:
Acta Pharmaceutica Sinica
Year:
2011
Document type:
Article